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Letters to the Editorinstitutional review board of Fudan
University Shanghai Cancer Center.
Prospective randomized research of
neoadjuvant therapy will be per-
formed soon. We are willing to share
the results with our colleagues
throughout the world and relate our
experience for the treatment of
esophageal cancer.
Bin Li, MDa,b
Haiquan Chen, MDa,b
aDepartment of Thoracic Surgery
Fudan University Shanghai
Cancer Center
Shanghai, China
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AND HEART TRANSPLANT
To the Editor:
Grubb and colleagues1 report a case
of a 60-year-old man with history of
nonischemic cardiomyopathy and
end-stage heart failure who underwent
placement of a left ventricular assist
device (LVAD) and replacement of
a mechanical aortic valve with a por-
cine prosthesis complicated by multi-
ple driveline infections. The heart
transplant was the last option. During
the operation, the authors reported
‘‘episodes of hypotension during the
extensive lysis of adhesions forThe Journal[LVAD] removal. Intermittent boluses
of phenylephrine were administered
to maintain a sufficient mean arterial
pressure.’’ Subsequently, a methylene
blue (MB) 1 mg/kg bolus followed by
continuous infusion of 0.5 mg/kg/hour
was administered. Postoperatively, the
patient presented signals of serotonin
syndrome, presumably a consequence
of an interaction between MB and an-
tidepressant medications.
This report has two crucial points:
the possibility of serotonin syndrome
triggered by the association MB and
antidepressants, and the routine use
of MB to handle vasoplegia in the mi-
lieu of heart transplant. Kofidis and
colleagues2 reported the first experi-
ence of vasoplegia treatment with
MB after heart transplant and pointed
out that this drug deserves attention
because of its catecholamine-saving
effect, thus preventing possible mal-
perfusion. Kofidis and colleagues’ re-
port is unique in the literature
regarding using MB to treat vasople-
gia associated with heart transplant.
In 2009, my colleagues and I pub-
lished an article3 discussing 15 years
of questions, answers, doubts, and cer-
tainties regarding MB for vasoplegic
syndrome treatment in heart surgery.
In summary, our report shared that
heparin and angiotensin-converting
enzyme inhibitors are risk factors; in
the recommended doses it is safe
(the lethal dose is 40 mg/kg); the use
of MB does not induce endothelial
dysfunction; the MB effect appears
in cases of nitric oxide up-regulation;
MB is not a vasoconstrictor—by
blocking the cyclic guanosine 3,
5-monophosphate (cGMP) pathway
it releases the cyclic adenosine
monophosphate (cAMP) pathway,
facilitating the norepinephrine vaso-
constrictor effect; the most used dos-
age is 2 mg/kg administered
intravenously as a bolus followed by
the same continuous infusion because
plasmatic concentrations strongly de-
cays in the first 40 minutes; and there
is a possible window of opportunity
for MB’s effectiveness.3of Thoracic and Cardiovascular SurgeTo circumvent the morbidity and
mortality associated with vasoplegic
syndrome Grubb and colleagues1 im-
plemented an intraoperative protocol
that includes administration of MB
for vasoplegic syndrome resistant to
vasopressor drugs. Because serotonin
syndrome only occurs in a small per-
centage of patients and is treatable
with benzodiazepines and supportive
care, and the possibility of serotonin
syndrome is less than the risk of un-
treated vasoplegia and potential end-
organ injury and graft loss, we have
continued to include MB in the
management of severe vasoplegic
syndrome.
I congratulate Grubb and colleagues
for reporting the association between
MB and antidepressants that may cause
serotonin syndrome. Although, to be
honest, as a proponent of the use of
MB4,5 the purpose of my letter is to
suggest Grubb and colleagues publish
their MB experience in heart transplant.
It would be a valuable contribution to
the cardiac surgery literature.
Paulo Roberto B. Evora, MD, PhD
Department of Surgery and Anatomy
Ribeir~ao Preto Faculty of Medicine
University of S~ao Paulo
Ribeir~ao Preto, S~ao Paulo, Brazil
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